Castle Biosciences Incorporated: Clinical Trials

3 terminated, 1 completed, 1 recruiting. .

Follow Castle Biosciences Incorporated: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares Nevisense electrical impedance spectroscopy - Atopic Dermatitis		Recruiting	Castle Biosciences Incorporated	450	2026-06-04	2026-10-20
Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays Rectal Adenocarcinoma, Anal Adenocarcinoma		Terminated	Castle Biosciences Incorporated	3	2015-02-01	2018-01-25
5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results Cutaneous Melanoma		Terminated	Castle Biosciences Incorporated	301	2014-06-01	2021-10-08
Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes Cutaneous Melanoma		Terminated	Castle Biosciences Incorporated	72	2014-03-01	2021-10-08
5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes Uveal Melanoma		Completed	Castle Biosciences Incorporated	93	2010-03-01	2022-05-16

Conditions studied

Melanoma (2)  ·  Adenocarcinoma (1)  ·  Anus Neoplasms (1)  ·  Dermatitis, Atopic (1)  ·  Eczema (1)  ·  Rectal Neoplasms (1)  ·  Uveal Melanoma (1)

Countries

United States (4)

Top investigators

Robert Cook, PhD (4)

Results publications

PMID 34036233, PMID 34568719, PMID 27446211